Tags

Type your tag names separated by a space and hit enter

Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
Cancer Chemother Pharmacol. 2003 May; 51(5):376-84.CC

Abstract

BACKGROUND

BNP7787 (disodium 2,2'-dithio-bis-ethane sulfonate) was evaluated in a phase I clinical trial with paclitaxel and cisplatin to assess the safety and potential efficacy for preventing or reducing cisplatin- and paclitaxel-induced toxicities. During this trial the effects of BNP7787 administration on the total concentrations (oxidized plus free) of cysteine, homocysteine and GSH in plasma, free and total GSH in WBC and rate of urinary excretion of cysteine were studied. The pharmacokinetics of ultrafilterable (free, non-protein bound) platinum were also determined after cisplatin (75 mg/m(2)) treatment which followed paclitaxel (175 mg/m(2)) and BNP7787 (8.2 to 27.6 g/m(2)).

METHODS

Plasma thiols were measured by HPLC with fluorescence detection and platinum was measured by atomic absorption spectrophotometry.

RESULTS

BNP7787 administration produced a significant depletion of all plasma thiols in all the patients studied. Differences were noted in the kinetics of BNP7787-induced depletion of cysteine and other thiols. A significant depletion of cysteine occurred with a time lag of about 2 h after the end of BNP7787 infusion, while a reversible depletion of GSH and homocysteine occurred immediately following the start of BNP7787 infusion, with the plasma thiol/disulfide nadir corresponding to the end of infusion. The mean half-life of cysteine depletion following BNP7787 administration was 2.2 h, significantly longer than for homocysteine (0.23 h), or GSH (0.18 h; P<0.05 for both). A several-fold increase in the urinary excretion of cysteine occurred following BNP7787 administration in all patients. The BNP7787-induced thiol/disulfide depletion in plasma was not affected by cisplatin administration (P>0.05). BNP7787 administration had no effect on the ultrafilterable platinum pharmacokinetics. The 2-h lag in the depletion of cysteine, the most abundant thiol in plasma, suggests that the process may be related to the formation of free mesna from BNP7787 and that increased levels of mesna are not in circulation until after 2 h after BNP7787 administration. No effect of BNP7787 was seen on the GSH concentration in WBC, possibly reflecting the inability of these cells to take up BNP7787.

CONCLUSION

The results suggest that BNP7787 has the potential to enhance cisplatin antitumor activity by depleting the reactive thiols in plasma.

Authors+Show Affiliations

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. lakshmi.pendyala@roswellpark.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12682786

Citation

Pendyala, Lakshmi, et al. "Modulation of Plasma Thiols and Mixed Disulfides By BNP7787 in Patients Receiving Paclitaxel/cisplatin Therapy." Cancer Chemotherapy and Pharmacology, vol. 51, no. 5, 2003, pp. 376-84.
Pendyala L, Schwartz G, Smith P, et al. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemother Pharmacol. 2003;51(5):376-84.
Pendyala, L., Schwartz, G., Smith, P., Zdanowicz, J., Murphy, M., & Hausheer, F. (2003). Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemotherapy and Pharmacology, 51(5), 376-84.
Pendyala L, et al. Modulation of Plasma Thiols and Mixed Disulfides By BNP7787 in Patients Receiving Paclitaxel/cisplatin Therapy. Cancer Chemother Pharmacol. 2003;51(5):376-84. PubMed PMID: 12682786.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. AU - Pendyala,Lakshmi, AU - Schwartz,Gary, AU - Smith,Patrick, AU - Zdanowicz,Joseph, AU - Murphy,Michael, AU - Hausheer,Frederick, Y1 - 2003/04/08/ PY - 2002/09/20/received PY - 2003/01/15/accepted PY - 2003/4/19/pubmed PY - 2003/6/25/medline PY - 2003/4/19/entrez SP - 376 EP - 84 JF - Cancer chemotherapy and pharmacology JO - Cancer Chemother Pharmacol VL - 51 IS - 5 N2 - BACKGROUND: BNP7787 (disodium 2,2'-dithio-bis-ethane sulfonate) was evaluated in a phase I clinical trial with paclitaxel and cisplatin to assess the safety and potential efficacy for preventing or reducing cisplatin- and paclitaxel-induced toxicities. During this trial the effects of BNP7787 administration on the total concentrations (oxidized plus free) of cysteine, homocysteine and GSH in plasma, free and total GSH in WBC and rate of urinary excretion of cysteine were studied. The pharmacokinetics of ultrafilterable (free, non-protein bound) platinum were also determined after cisplatin (75 mg/m(2)) treatment which followed paclitaxel (175 mg/m(2)) and BNP7787 (8.2 to 27.6 g/m(2)). METHODS: Plasma thiols were measured by HPLC with fluorescence detection and platinum was measured by atomic absorption spectrophotometry. RESULTS: BNP7787 administration produced a significant depletion of all plasma thiols in all the patients studied. Differences were noted in the kinetics of BNP7787-induced depletion of cysteine and other thiols. A significant depletion of cysteine occurred with a time lag of about 2 h after the end of BNP7787 infusion, while a reversible depletion of GSH and homocysteine occurred immediately following the start of BNP7787 infusion, with the plasma thiol/disulfide nadir corresponding to the end of infusion. The mean half-life of cysteine depletion following BNP7787 administration was 2.2 h, significantly longer than for homocysteine (0.23 h), or GSH (0.18 h; P<0.05 for both). A several-fold increase in the urinary excretion of cysteine occurred following BNP7787 administration in all patients. The BNP7787-induced thiol/disulfide depletion in plasma was not affected by cisplatin administration (P>0.05). BNP7787 administration had no effect on the ultrafilterable platinum pharmacokinetics. The 2-h lag in the depletion of cysteine, the most abundant thiol in plasma, suggests that the process may be related to the formation of free mesna from BNP7787 and that increased levels of mesna are not in circulation until after 2 h after BNP7787 administration. No effect of BNP7787 was seen on the GSH concentration in WBC, possibly reflecting the inability of these cells to take up BNP7787. CONCLUSION: The results suggest that BNP7787 has the potential to enhance cisplatin antitumor activity by depleting the reactive thiols in plasma. SN - 0344-5704 UR - https://www.unboundmedicine.com/medline/citation/12682786/Modulation_of_plasma_thiols_and_mixed_disulfides_by_BNP7787_in_patients_receiving_paclitaxel/cisplatin_therapy_ L2 - https://dx.doi.org/10.1007/s00280-003-0587-y DB - PRIME DP - Unbound Medicine ER -